904H-0
HMB-45 + MART-1 (Melan A) + Tyrosinase (HMB-45 + A103 + T311) Mouse Monoclonal Antibody
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
HMB-45+A103+T311, monoclonal
Application:
—
Citations:
10
biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
HMB-45+A103+T311, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
bottle of 1.0 mL predilute (904H-07), bottle of 7.0 mL predilute (904H-08)
manufacturer/tradename
Cell Marque®
isotype
IgG1κ, IgG1, IgG2a
shipped in
wet ice
storage temp.
2-8°C
General description
Anti-HMB-45 identifies immature melanosomes. It shows greater specificity for malignant melanomas and metastatic melanomas. MART-1 (also known as Melan A) is a melanocyte differentiation antigen. It is present in melanocytes of normal skin and retina, nevi and in more than 85% of melanomas. Tyrosinase is an enzyme integral in the process of melanin synthesis, and found in 85% to 90% of malignant melanomas. Given these statistics, this cocktail is ideally suited to detection of melanomas and melanocytic lesions.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
 IVD |  IVD |  IVD |  RUO |
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
M L Prasad et al.
The American journal of surgical pathology, 25(6), 782-787 (2001-06-08)
Malignant melanomas of the oral and sinonasal mucosa are rare tumors. Amelanotic variants can, on occasion, be difficult to recognize by routine light microscopy. Immunohistochemical studies may be needed for a final diagnosis. A number of new monoclonal antibodies to
Vinod B Shidham et al.
BMC cancer, 3, 15-15 (2003-05-09)
MART-1, Melan-A, and Tyrosinase have shown encouraging results for evaluation of melanoma micrometastases in sentinel lymph nodes, as compared to conventionally used S-100 protein and HMB-45. To achieve higher sensitivity, some studies recommend evaluation of three sections, each at intervals
Guy Orchard
British journal of biomedical science, 59(4), 196-202 (2003-02-08)
Incidence of malignant melanoma (MM) is rising rapidly throughout the Western world, and the number of melanocytic lesions removed for histological assessment has increased. MM can present with a myriad of histological appearances that make diagnosis problematic, particularly when dealing
L Vaggelli et al.
Tumori, 86(4), 346-348 (2000-10-04)
Elective lymph node dissection (ELND) for patients with malignant melanoma is still controversial. A possible alternative could be biopsy of the first tumor draining lymph node, the sentinel node (SN), which can be identified by means of radionuclide techniques. Our
T J de Vries et al.
The Journal of pathology, 193(1), 13-20 (2001-02-13)
With the recent availability of novel antibodies against melanoma antigens tyrosinase and MART-1, it is important to validate their usefulness in pathology practice and in screening patients for immunotherapy treatment. In the present study conducted by the Melanoma Cooperative Group
商品
IHC antibodies enhance dermatopathology beyond H&E stained slides, improving techniques and applications for dermatological research.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持